This study reveals the mechanism by which PD-1 and CD40 co-stimulation synergistically activates both innate and adaptive immunity in advanced melanoma, providing direct experimental evidence for designing novel 'in situ vaccine' strategies, particularly suitable for converting immunologically cold tumors.
Literature Overview
This article, titled "Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study," published in the journal Cancer Discovery, systematically investigates the safety and immunological mechanisms of intratumoral CD40 agonist sotigalimab combined with systemic PD-1 blockade pembrolizumab in patients with metastatic melanoma. Through multi-omics dynamic monitoring, the study reveals that this combination rapidly activates antigen-presenting cells (APC), promotes T-cell clonal expansion, and induces systemic antitumor immunity, with significant responses also observed in non-injected lesions. These findings offer a new approach to overcoming resistance to immune checkpoint inhibitors.Background Knowledge
1. Although PD-1 inhibitors have significantly improved treatment outcomes for advanced melanoma, nearly half of patients exhibit primary or acquired resistance, primarily due to a lack of T-cell infiltration or defects in antigen presentation within the tumor microenvironment. 2. CD40, a member of the tumor necrosis factor receptor superfamily, is highly expressed on dendritic cells (DCs) and macrophages. CD40 agonists promote DC maturation, enhance T-cell priming, and reprogram tumor-associated macrophages toward an M1 phenotype. However, systemic administration of CD40 agonists often causes severe hepatotoxicity, limiting their clinical utility. 3. This study's innovation lies in using intratumoral injection to activate local APCs, triggering a systemic immune response via an 'in situ vaccine' effect—avoiding systemic toxicity—while combining PD-1 blockade to reverse T-cell exhaustion, thereby achieving synergistic antitumor effects. This strategy precisely targets the microenvironmental deficiencies of immunologically cold tumors and holds high translational potential.
Research Methods and Experiments
The study employed a phase I/II clinical trial design, enrolling 32 PD-1 treatment-naïve patients with advanced melanoma who received intratumoral sotigalimab (0.1–10 mg) plus intravenous pembrolizumab. Longitudinal samples from injected and non-injected tumor lesions and peripheral blood were analyzed using multi-omics approaches, including single-cell RNA sequencing (scRNA-seq), single-cell ATAC-seq, multiplex immunofluorescence (mIF), mass cytometry (CyTOF), and TCR sequencing, to systematically characterize dynamic changes in the immune microenvironment. Key experiments included assessing CD40 pathway activation 24 hours post-injection, evaluating T-cell infiltration and clonality at week 6, and using pseudotime trajectory analysis to reveal epigenetic reprogramming of APCs and T cells.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides clear mechanistic support for drug development: an 'in situ vaccine' strategy targeting CD40 can effectively overcome immunosuppressive microenvironments in cold tumors, particularly benefiting patients lacking T-cell infiltration. The induced systemic immune response does not require pre-existing tumor-specific T cells, thereby expanding the applicability of immunotherapy.
For clinical monitoring, early peripheral blood signals of APC activation (e.g., CD83, PSMB8) may serve as predictive pharmacodynamic biomarkers, outperforming traditional imaging assessments. Additionally, the degree of T-cell clonal sharing could be used as a dynamic efficacy monitoring indicator.
For disease modeling, the study suggests the need to develop animal models incorporating a human immune system and multiple metastatic lesions to accurately simulate the 'abscopal effect.' Humanized mouse models combined with CD40 agonists and PD-1 blockade can further validate the generalizability of this approach across tumor types.
Conclusion
This study establishes the safety and efficacy of intratumoral CD40 agonist combined with PD-1 blockade in advanced melanoma. The core mechanism involves activating antigen-presenting cells to initiate an 'in situ vaccine' effect, driving systemic T-cell responses that control non-injected lesions. This strategy not only offers new hope for patients resistant to immune checkpoint inhibitors but also redefines the role of local therapy in systemic immune activation. From bench to bedside, this approach underscores the value of multi-omics dynamic monitoring in personalized immunotherapy, suggesting that future efficacy assessments should incorporate APC activation and T-cell clonal dynamics. For melanoma care systems, this research advances the paradigm shift from 'single-target blockade' to 'immune microenvironment remodeling,' laying the foundation for next-generation combination immunotherapies.
